1. Home
  2. UA vs CELC Comparison

UA vs CELC Comparison

Compare UA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UA
  • CELC
  • Stock Information
  • Founded
  • UA 1996
  • CELC 2011
  • Country
  • UA United States
  • CELC United States
  • Employees
  • UA N/A
  • CELC N/A
  • Industry
  • UA Apparel
  • CELC Medical Specialities
  • Sector
  • UA Consumer Discretionary
  • CELC Health Care
  • Exchange
  • UA Nasdaq
  • CELC Nasdaq
  • Market Cap
  • UA 2.8B
  • CELC 2.8B
  • IPO Year
  • UA N/A
  • CELC 2017
  • Fundamental
  • Price
  • UA $4.65
  • CELC $71.27
  • Analyst Decision
  • UA
  • CELC Strong Buy
  • Analyst Count
  • UA 0
  • CELC 5
  • Target Price
  • UA N/A
  • CELC $69.40
  • AVG Volume (30 Days)
  • UA 4.0M
  • CELC 1.6M
  • Earning Date
  • UA 11-06-2025
  • CELC 11-13-2025
  • Dividend Yield
  • UA N/A
  • CELC N/A
  • EPS Growth
  • UA N/A
  • CELC N/A
  • EPS
  • UA 0.23
  • CELC N/A
  • Revenue
  • UA $5,114,713,000.00
  • CELC N/A
  • Revenue This Year
  • UA N/A
  • CELC N/A
  • Revenue Next Year
  • UA $2.34
  • CELC N/A
  • P/E Ratio
  • UA $20.14
  • CELC N/A
  • Revenue Growth
  • UA N/A
  • CELC N/A
  • 52 Week Low
  • UA $4.56
  • CELC $7.58
  • 52 Week High
  • UA $10.62
  • CELC $83.00
  • Technical
  • Relative Strength Index (RSI)
  • UA 43.10
  • CELC 71.94
  • Support Level
  • UA $4.56
  • CELC $64.61
  • Resistance Level
  • UA $4.71
  • CELC $73.06
  • Average True Range (ATR)
  • UA 0.13
  • CELC 4.36
  • MACD
  • UA 0.01
  • CELC 2.44
  • Stochastic Oscillator
  • UA 26.48
  • CELC 69.85

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: